云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01952 云顶新耀

已收盘 07-23 16:08:06

25.580

-0.140

-0.54%

最高26.040	最低25.120	成交量118.55万
今开26.200	昨收25.720	日振幅3.58%
总市值90.55亿	流通市值90.55亿	总股本3.54亿
成交额3,022万	换手率0.33%	流通股本3.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01952","market":"HK","secType":"STK","nameCN":"云顶新耀","latestPrice":25.58,"timestamp":1784794086003,"preClose":25.72,"halted":0,"volume":1185532,"delay":0,"changeRate":-0.005443234836702978,"floatShares":354000000,"shares":354000000,"eps":-1.0308396126553494,"marketStatus":"已收盘","change":-0.14,"latestTime":"07-23 16:08:06","open":26.2,"high":26.04,"low":25.12,"amount":30215644,"amplitude":0.03577,"askPrice":25.58,"askSize":1500,"bidPrice":25.54,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":-1.0794859763986355,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":5,"adr":0,"listingDate":1602172800000,"exchange":"SEHK","adjPreClose":25.72,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.308961,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01952/tweets","defaultTab":"tweets","newsList":[{"id":"1117644772","title":"异动解读｜云顶新耀盘中上涨5.18%，生物科技板块集体反弹叠加多重利好催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1117644772","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117644772?lang=zh_cn&edition=full","pubTime":"2026-07-20 13:11","pubTimestamp":1784524319,"startTime":"0","endTime":"0","summary":"7月20日，云顶新耀盘中上涨5.18%，报26.0港元，成交额4848.98万港元。消息面上，此前7月17日生物科技板块集体重挫，云顶新耀曾跌7.83%，本次上涨主要受板块反弹带动。行业内康方生物涨6.34%、荣昌生物涨8.72%、三生制药涨5.26%、百济神州涨3.29%，板块回暖明显。多重利好叠加板块技术性反弹，共同构成本轮上行动力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198926396","title":"云顶新耀（01952）根据2026年股份计划授出473,178份购股权及最多1,398,527份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1198926396","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198926396?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:11","pubTimestamp":1784297493,"startTime":"0","endTime":"0","summary":"2026年7月17日，云顶新耀有限公司公告称，董事会已根据公司于2026年2月24日采纳的2026年股份计划批准两项授出：。1）向14名购股权承授人授出473,178份购股权；1,368,527份奖励按4年平均归属，每满1年归属25%；其中793,807份奖励需承授人达成指定考绩评级。根据2026年股份计划，总可供授出股份上限为35,358,115股。截至本公告日，扣除本次授出后，尚有33,486,410股股份可供未来授出。公司表示，授出购股权及奖励旨在吸引、挽留并激励核心人才，进一步促进公司及股东整体利益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652715286","title":"云顶新耀(01952.HK)授出47.3万份购股权及139.85万份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2652715286","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652715286?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:10","pubTimestamp":1784297444,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1583","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652628671","title":"云顶新耀(01952)授出47.3万份购股权及139.85万份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2652628671","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652628671?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:10","pubTimestamp":1784297444,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀(01952)发布公告，于2026年7月17日，董事会根据2026年股份计划授出47.3万份购股权;及根据2026年股份计划授出139.85万份奖励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01952","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138533032","title":"异动解读｜云顶新耀盘中下跌7.83%，生物科技板块集体重挫拖累个股","url":"https://stock-news.laohu8.com/highlight/detail?id=1138533032","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138533032?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:31","pubTimestamp":1784255503,"startTime":"0","endTime":"0","summary":"7月17日，云顶新耀盘中下跌7.83%，报26.38港元，成交额4969.62万港元。消息面上，公司暂无重大利空公告，本次下跌主要受生物科技板块集体回调拖累。板块内主要个股普遍承压，康方生物跌11.1%、三生制药跌11.22%、科伦博泰生物跌5.42%、信达生物跌4.88%、百济神州跌2.46%，板块抛压显著。此前7月15日，云顶新耀曾因EVER001授权交割落地及板块强势联动上涨6.67%，短期获利盘回吐叠加板块系统性回调，构成本轮下行压力。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651440812","title":"2026版国家基药目录发布！云顶新耀三大重症急救核心用药在列，思他宁全新纳入","url":"https://stock-news.laohu8.com/highlight/detail?id=2651440812","media":"天府财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651440812?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:39","pubTimestamp":1784209140,"startTime":"0","endTime":"0","summary":"早在2015年，罗氏芬即被列入国家基药目录，本次顺利延续国家基本药物身份。此次三款药物悉数被列入新版国家基药目录，将补齐县域、社区诊疗设备用药短板，统一上下级医院核心急救用药，推动分级诊疗落地，实现临床诊疗标准化，构建完整院内急救用药闭环，规范诊疗路径。2026版国家基药目录聚焦临床急重症痛点，罗氏芬、亚宁定、思他宁三款核心药物同步覆盖感染、心血管急救、消化道危重症三大领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-16/doc-inihzmmu4372064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1161","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149577314","title":"异动解读｜云顶新耀盘中上涨6.67%，多重利好叠加生物科技板块强势共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1149577314","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149577314?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:10","pubTimestamp":1784085007,"startTime":"0","endTime":"0","summary":"7月15日，云顶新耀盘中上涨6.67%，报29.44港元，成交额6326.44万港元。消息面上，公司近期利好密集释放。7月8日，公司宣布完成EVER001与Travere Therapeutics的独家授权合作协议交割，该交易涉及1.125亿美元首付款及最高10.3亿美元里程碑付款，标志着全球化战略取得关键进展。同日，生物科技板块整体表现强势，科伦博泰生物涨11.3%、信达生物涨9.33%、三生制药涨9.03%，板块联动亦对股价形成支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649546963","title":"云顶新耀完成EVER001对外授权交割","url":"https://stock-news.laohu8.com/highlight/detail?id=2649546963","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649546963?lang=zh_cn&edition=full","pubTime":"2026-07-08 14:34","pubTimestamp":1783492440,"startTime":"0","endTime":"0","summary":"【云顶新耀完成EVER001对外授权交割】云顶新耀（HKEX1952.HK）宣布，已根据协议条款完成与TravereTherapeutics,Inc.（NASDAQ:TVTX，以下简称“TravereTherapeutics”）关于EVER001（希布替尼，civorebrutinib）的独家授权许可与合作协议交割，表明该交易已满足必要监管程序等约定交割条件，充分体现了公司承诺兑现的执行能力。双方合作将正式进入实施阶段，并将共同推进EVER001的后续开发与商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798294823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1161","BK1574","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649954218","title":"创新药板块走低 科伦博泰生物(06990)跌7.67% 当前板块仍处估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2649954218","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649954218?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:08","pubTimestamp":1783480087,"startTime":"0","endTime":"0","summary":"有研究指，创新药板块年内曾两轮短期反弹，本轮行情依托政策组合、高含金量海外交易、机构持续加仓三大不同支撑，但机构表示当前仅为估值修复行情，基本面全面反转仍需中期、三季度财报验证，后续走势重点跟踪企业盈利兑现与CGT正式政策落地进度。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985359","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0819121731.USD","159992","BK1515","LU0348784397.USD","06855","BK1141","BK1583","CZA","LU0196878994.USD","LU3063872942.SGD","IE00B0JY6N72.USD","06978","LU0320764599.SGD","01477","REVS","02268","06990","LU0516422440.USD","SG9999014674.SGD","LU0326950275.SGD","IBBQ","LU2476274308.USD","LU0140636845.USD","06955","LU0572944931.SGD","LU0516423091.SGD","LU0417516571.SGD","LU0051755006.USD","01952","SG9999002463.SGD","02269","02186","LU0348783233.USD","BK1521","LU0979878070.USD","LU1880383366.USD","00460","BK1600","LU0456846285.SGD","LU0588546209.SGD","09926","01672","LU1046422090.SGD","02359","LU0052750758.USD","KURE","LU2242644610.SGD","01530","BK1191","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170701089","title":"云顶新耀6月股份变动月报：股本维持稳定，新增6,900股","url":"https://stock-news.laohu8.com/highlight/detail?id=1170701089","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170701089?lang=zh_cn&edition=full","pubTime":"2026-07-07 17:25","pubTimestamp":1783416307,"startTime":"0","endTime":"0","summary":"云顶新耀有限公司于2026年7月7日发布2026年6月股份变动月报。报告显示，公司法定股本维持在500,000,000股，注册股本仍为USD 50,000，未发生变动。根据月报，截至2026年6月30日，公司已发行股份由上月底的353,822,975股增至353,829,875股，新增6,900股。期权与激励计划方面，本月主要变动来自首次公开发售后购股权计划的行权，合计行使了6,900股期权，并筹资合计HKD 118,222.8；另有119,982股期权失效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139898790","title":"异动解读｜云顶新耀盘中下跌5.03%，报27.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139898790","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139898790?lang=zh_cn&edition=full","pubTime":"2026-07-07 14:33","pubTimestamp":1783406039,"startTime":"0","endTime":"0","summary":"7月7日，云顶新耀盘中下跌5.03%，报27.2港元/股，成交额5709.01万港元。云顶新耀所在的生物科技行业中，个股普遍走弱，其中康方生物跌5.0%，信达生物跌4.03%，百济神州跌3.67%，三生制药跌6.79%，科伦博泰生物跌2.77%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181519976","title":"异动解读｜云顶新耀盘中上涨7.05%，多重BD催化叠加生物科技板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1181519976","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181519976?lang=zh_cn&edition=full","pubTime":"2026-07-06 10:37","pubTimestamp":1783305458,"startTime":"0","endTime":"0","summary":"7月6日，云顶新耀盘中上涨7.05%，报29.76港元，成交额1.1亿港元。此外，公司此前密集完成多项BD交易，包括将EVER001全球权益授予Travere获1.125亿美元首付款、引进DMX-200及LNZ100等资产，主要股东康桥资本自去年12月累计增持超1.725亿港元。当日生物科技板块整体走强，信达生物涨7.18%、科伦博泰生物涨6.41%、荣昌生物涨6.26%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174448477","title":"异动解读｜云顶新耀盘中上涨8.16%，PCSK9抑制剂上市申请获受理叠加多重利好催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1174448477","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174448477?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:22","pubTimestamp":1782958929,"startTime":"0","endTime":"0","summary":"7月2日，云顶新耀盘中上涨8.16%，报25.8港元，成交额5032.84万港元。消息面上，公司近日密集释放利好：6月26日，NMPA正式受理其第三代PCSK9抑制剂乐瑞泊生物制品上市许可申请，用于降低成人高胆固醇血症患者LDL-C水平，预计最快于明年获批上市。该产品全球III期数据显示LDL-C降幅达65.9%，具备同类最佳潜力。此外，公司6月24日宣布与海南合瑞就布地奈德肠溶胶囊达成商业化合作，由云顶新耀负责首仿药在中国大陆的商业化，进一步巩固肾病领域市场地位。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647299558","title":"从资产清单到现金流：云顶新耀重估的真正理由","url":"https://stock-news.laohu8.com/highlight/detail?id=2647299558","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647299558?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:19","pubTimestamp":1782818340,"startTime":"0","endTime":"0","summary":"此前潮药Bar曾讨论过为什么长期看好云顶新耀，但市场对公司的核心质疑一直没有消失：这家公司究竟是一家靠license-in和耐赋康支撑的商业化公司，还是正在形成一套可复制的亚洲Biopharma平台能力？最近一轮密集BD，把这个问题重新摆到了台面上。　　因此，本文的主旨需要更集中：云顶新耀的估值锚，正在从单品rNPV迁移到平台现金流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-30/doc-inifexfn4707566.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-30/doc-inifexfn4707566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","159399","BK1583","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647932656","title":"港股异动 | 云顶新耀(01952.HK)涨超7% NMPA已正式受理第三代PCSK9抑制剂乐瑞泊®生物制品上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2647932656","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647932656?lang=zh_cn&edition=full","pubTime":"2026-06-29 14:46","pubTimestamp":1782715615,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01952","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647328063","title":"格隆汇2026中期策略峰会“All in 硅基新纪元”暨“金格奖”——卓越公司榜单全部揭晓！","url":"https://stock-news.laohu8.com/highlight/detail?id=2647328063","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647328063?lang=zh_cn&edition=full","pubTime":"2026-06-29 13:08","pubTimestamp":1782709733,"startTime":"0","endTime":"0","summary":"本次评选共设有14个奖项","market":"us","thumbnail":"https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/9dec8-575c2ec7-abca-4b10-b7d8-3bd3f2cd0682.jpg?guru_height=741&guru_width=1140&guru_size=148310"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5373783","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06979","00917","000951","01519","01384","02511","000338","300364","02273","01497","02555","02553","02526","02279","00780","02105","001248","002779","002352","02121","09678","01833","002594","01021","02643","02687","03690","02661","06668","03692","000039","01952","09959","06963","02170","01024","02590","02408","09880","002714","002600","01951","07688","09878","09992","02729","00600","02718","300760","01768"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152320377","title":"异动解读｜云顶新耀盘中下跌5.48%，耐赋康专利和解引发独家溢价削弱担忧持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1152320377","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152320377?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:21","pubTimestamp":1782444104,"startTime":"0","endTime":"0","summary":"6月26日，云顶新耀盘中下跌5.48%，报22.78港元/股，成交额6341.99万港元，延续前一日跌势。耐赋康作为公司核心营收产品，全年销售收入突破14亿元，占公司总收入80%以上。此前公司曾通过广州知识产权法院获得诉前行为保全裁定，如今从对簿公堂转向合作，叠加石药集团布地奈德肠溶胶囊亦已于5月获批，市场对耐赋康独家溢价被削弱的担忧持续升温，股价连续两日承压下行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153347457","title":"异动解读｜云顶新耀盘中下跌5.15%，耐赋康专利和解允许首仿药上市引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1153347457","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153347457?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:15","pubTimestamp":1782353753,"startTime":"0","endTime":"0","summary":"6月25日，云顶新耀盘中下跌5.15%，报23.8港元/股，成交额3150.07万港元。消息面上，公司于6月24日宣布与海南合瑞制药就耐赋康相关专利达成谅解，海南合瑞已于去年12月获国家药监局批准的布地奈德肠溶胶囊将获准在中国大陆市场上市，由云顶新耀负责其商业化。耐赋康作为公司核心营收产品，首仿药正式获准入市被市场解读为独家溢价削弱的信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897136","title":"明星肾病药专利大和解！首仿药获准上市，云顶新耀负责商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897136","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645897136?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:07","pubTimestamp":1782299220,"startTime":"0","endTime":"0","summary":"两家药企围绕一款明星肾病产品的专利战以和解告终。6月24日，云顶新耀（1952.HK）发布消息称，公司与海南合瑞制药股份有限公司（简称“海南合瑞”）就布地奈德肠溶胶囊（商品名：耐赋康）相关专利达成谅解，并就海南合瑞于2025年12月获得中国国家药品监督管理局批准的布地奈德肠溶胶囊开展商业化合作。海南合瑞的布地奈德肠溶胶囊将获准在中国大陆市场上市，由云顶新耀负责其商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606243781570384.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781570384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","BK1583","IPOS","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645861935","title":"云顶新耀(01952)与海南合瑞就布地奈德肠溶胶囊达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2645861935","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645861935?lang=zh_cn&edition=full","pubTime":"2026-06-24 12:34","pubTimestamp":1782275687,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，公司与海南合瑞制药股份有限公司就海南和瑞的布地奈德肠溶胶囊达成商业化合作。根据该合作，海南合瑞的布地奈德肠溶胶囊将获准在中国大陆市场上市，并由公司负责其商业化。该合作将有助于提升患者对耐赋康与海南合瑞布地奈德肠溶胶囊的用药选择。2019年6月，公司与Calliditas签订独家授权合约，授权公司在中国内地、香港、澳门、中国台湾和新加坡开发以及商业化耐赋康的权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","01952","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.everestmedicines.com","stockEarnings":[{"period":"1week","weight":-0.1113},{"period":"1month","weight":0.0086},{"period":"3month","weight":-0.3011},{"period":"6month","weight":-0.3873},{"period":"1year","weight":-0.6393},{"period":"ytd","weight":-0.3045}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"云顶新耀有限公司是一家主要从事创新药及疫苗研发、临床开发、制造及商业化的生物制药公司。该公司已建立跨肾病、抗感染及自身免疫性疾病的产品管线。该公司的产品管线包括用于肾病治疗领域的耐赋康（TARPEYO）、用于治疗包括临床常见的革兰氏阴性菌、革兰氏阳性菌、厌氧菌等多重耐药菌的感染的依嘉（依拉环素）等产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.01035},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039331},{"month":3,"riseRate":0.333333,"avgChangeRate":0.002002},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.092533},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.045773},{"month":6,"riseRate":0.666667,"avgChangeRate":0.224714},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.087506},{"month":8,"riseRate":0.2,"avgChangeRate":-0.112869},{"month":9,"riseRate":0.6,"avgChangeRate":0.046163},{"month":10,"riseRate":0.4,"avgChangeRate":-0.024036},{"month":11,"riseRate":0.5,"avgChangeRate":0.086142},{"month":12,"riseRate":0.666667,"avgChangeRate":0.131823}],"exchange":"SEHK","name":"云顶新耀","nameEN":"EVEREST MED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"云顶新耀,01952,云顶新耀股票,云顶新耀股票老虎,云顶新耀股票老虎国际,云顶新耀行情,云顶新耀股票行情,云顶新耀股价,云顶新耀股市,云顶新耀股票价格,云顶新耀股票交易,云顶新耀股票购买,云顶新耀股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"云顶新耀(01952)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供云顶新耀(01952)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}